Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. Issue 10 (24th August 2019)

• Record Type: Journal Article
• Authors: Baidoun, Firas; Chen, Dong; Patnaik, Mrinal; Gangat, Naseema; Begna, Kebede; Elliott, Michelle; Hogan, William; Litzow, Mark; Al-Kali, Aref
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 10(2019)
• Page Start: 2483
• Page End: 2487
• Publication Date: 2019-08-24
• Subjects: Myelodysplastic syndrome -- unclassifiable -- World Health Organization -- overall survival; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2019.1581930
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Myelodysplastic syndrome unclassifiable (MDS-U) is a small subtype of myelodysplastic syndromes (MDS). However, rare literature exists in terms of natural progression and clinical outcome of patients with MDS-U. In the present study, we investigated the characteristics and the clinical outcomes of patients categorized as MDS-U based on 2008 World Health Organization criteria (WHO) in a single center comparing to other MDS groups. Out of eight hundred and two patients who met WHO criteria for MDS at our institution, ninety patients (11%) were initially classified as MDS-U. Upon pathological review, only half of the cases were confirmed to be MDS-U. With follow up, half of the MDS-U cases were reclassified to another subtype. We found neither significant difference in median overall survival nor in risk of transformation to acute myeloid leukemia when comparing MDS-U to other MDS groups. Additional larger studies are needed to confirm our results.